Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335695 (US9737544, Compound 13) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet  | PC cid PC sid UniChem | US Patent | n/a | n/a | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335677 (US9737544, Compound 6) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 31.6 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335695 (US9737544, Compound 13) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 50.1 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335682 (US9737544, Compound 14) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 63.1 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335681 (US9737544, Compound 10) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 63.1 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335680 (US9737544, Compound 9) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 79.4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335695 (US9737544, Compound 13) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 79.4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335680 (US9737544, Compound 9) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335677 (US9737544, Compound 6) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335686 (US9737544, Compound 18) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 100 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335681 (US9737544, Compound 10) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 126 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335677 (US9737544, Compound 6) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 126 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335679 (US9737544, Compound 8) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335682 (US9737544, Compound 14) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335681 (US9737544, Compound 10) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335680 (US9737544, Compound 9) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335679 (US9737544, Compound 8) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 158 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335686 (US9737544, Compound 18) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 200 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335696 (US9737544, Compound 11) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 200 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335695 (US9737544, Compound 13) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335677 (US9737544, Compound 6) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335686 (US9737544, Compound 18) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335696 (US9737544, Compound 11) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335673 (US9737544, Compound 2) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335678 (US9737544, Compound 7) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 251 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335678 (US9737544, Compound 7) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 316 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335682 (US9737544, Compound 14) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 398 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335677 (US9737544, Compound 6) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335675 (US9737544, Compound 4) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335678 (US9737544, Compound 7) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335680 (US9737544, Compound 9) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335697 (US9737544, Compound 15) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335673 (US9737544, Compound 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335679 (US9737544, Compound 8) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335684 (US9737544, Compound 16) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335675 (US9737544, Compound 4) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 501 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335682 (US9737544, Compound 14) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335695 (US9737544, Compound 13) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335697 (US9737544, Compound 15) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335696 (US9737544, Compound 11) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335697 (US9737544, Compound 15) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335681 (US9737544, Compound 10) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 631 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335675 (US9737544, Compound 4) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 794 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335686 (US9737544, Compound 18) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 794 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335685 (US9737544, Compound 17) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 794 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335685 (US9737544, Compound 17) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 794 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335673 (US9737544, Compound 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 794 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335672 (US9737544, Compound 1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335676 (US9737544, Compound 5) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335678 (US9737544, Compound 7) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335682 (US9737544, Compound 14) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335693 (US9737544, Compound 12) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335684 (US9737544, Compound 16) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335684 (US9737544, Compound 16) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335676 (US9737544, Compound 5) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335676 (US9737544, Compound 5) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335684 (US9737544, Compound 16) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335689 (US9737544, Compound 23) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335689 (US9737544, Compound 23) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335693 (US9737544, Compound 12) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335674 (US9737544, Compound 3) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335678 (US9737544, Compound 7) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335685 (US9737544, Compound 17) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335693 (US9737544, Compound 12) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335696 (US9737544, Compound 11) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335674 (US9737544, Compound 3) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335679 (US9737544, Compound 8) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335681 (US9737544, Compound 10) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335685 (US9737544, Compound 17) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335697 (US9737544, Compound 15) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335673 (US9737544, Compound 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335675 (US9737544, Compound 4) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335676 (US9737544, Compound 5) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335672 (US9737544, Compound 1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335672 (US9737544, Compound 1) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335674 (US9737544, Compound 3) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335675 (US9737544, Compound 4) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335676 (US9737544, Compound 5) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335689 (US9737544, Compound 23) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335693 (US9737544, Compound 12) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.26E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335689 (US9737544, Compound 23) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.26E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335673 (US9737544, Compound 2) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.26E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335680 (US9737544, Compound 9) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.26E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335687 (US9737544, Compound 20) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335674 (US9737544, Compound 3) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335686 (US9737544, Compound 18) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335696 (US9737544, Compound 11) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335687 (US9737544, Compound 20) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.51E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335697 (US9737544, Compound 15) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.51E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335694 (US9737544, Compound 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.51E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335688 (US9737544, Compound 21) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.16E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335688 (US9737544, Compound 21) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.01E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335685 (US9737544, Compound 17) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.01E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335694 (US9737544, Compound 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.01E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335674 (US9737544, Compound 3) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.31E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335684 (US9737544, Compound 16) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.94E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335693 (US9737544, Compound 12) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.94E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335687 (US9737544, Compound 20) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335694 (US9737544, Compound 26) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335688 (US9737544, Compound 21) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335689 (US9737544, Compound 23) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335691 (US9737544, Compound 24) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335687 (US9737544, Compound 20) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335691 (US9737544, Compound 24) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335691 (US9737544, Compound 24) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335691 (US9737544, Compound 24) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335687 (US9737544, Compound 20) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335688 (US9737544, Compound 21) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335692 (US9737544, Compound 25) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335672 (US9737544, Compound 1) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335691 (US9737544, Compound 24) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335672 (US9737544, Compound 1) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335692 (US9737544, Compound 25) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335692 (US9737544, Compound 25) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM335694 (US9737544, Compound 26) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335694 (US9737544, Compound 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 and tyrosine-protein kinase TIE-2 (KDR and TIE2) (Homo sapiens (Human)) | BDBM335692 (US9737544, Compound 25) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 2 (Homo sapiens (Human)) | BDBM335692 (US9737544, Compound 25) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 4 (Homo sapiens (Human)) | BDBM335679 (US9737544, Compound 8) | PDB KEGG UniProtKB/SwissProt DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM335688 (US9737544, Compound 21) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
ASTEX THERAPEUTICS LIMITED US Patent | Assay Description In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit... | US Patent US9737544 (2017) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
